It gives an accurate picture of BD in pharma. For those in the business Serres, Amazon, March, Help Centre.
- Valuation in Life Sciences: A Practical Guide.
- Tarot for Your Self : A Workbook for Personal Transformation Second Edition?
- The USA, ILO, UNESCO and IAEA: Politicization and Withdrawal in the Specialized Agencies.
- Revisionist Revolution in Vygotsky Studies: The State of the Art?
- About this book?
My Wishlist Sign In Join. Be the first to write a review.
Add to Wishlist. Ships in 15 business days.
Valuation in Life Sciences
Link Either by signing into your account or linking your membership details before your order is placed. Description Table of Contents Product Details Click on the cover image above to read some pages of this book! Industry Reviews From the reviews: "'Valuation in Life Sciences: A Practical Guide' leads readers step by step through the theory of life sciences valuation. Mathews, Amazon, December, "The authors always keep the necessary rigour to make the book a valuable reference to professionals such as business developers, investment bankers, or analysts.
Introduction p. All Rights Reserved. More Books in Finance See All. From 0 To Properties In 3. In Stock. Banking Bad.
Valuation in Life Sciences: A Practical Guide - Boris Bogdan, Ralph Villiger - Google книги
The Richest Man in Babylon. Security Analysis Principles and Technique. Principles of Investments 1st Edition. Market Wizards Interviews with Top Traders. Australian Residential Property Development for Investors. A Practical Introduction to Taxation Law Item Added: Valuation in Life Sciences.
View Wishlist. Responsibility Boris Bogdan, Ralph Villiger. Edition 3rd ed. Imprint Berlin : Springer, c Physical description xi, p. Online Available online. More options.
Laura dans tous ses états…
Find it at other libraries via WorldCat Limited preview. Contributor Villiger, Ralph. SpringerLink Online service. Bibliography Includes bibliographical references p. Contents Basics of Valuation.
https://nuekilllessri.ga Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow and real options, the authors demonstrate how to value projects, patents, licences, firms and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.
Ralph Villiger and Boris Bogdan have written what is sure to become the industry standard reference for valuation of pharmaceutical and biotechnology projects and companies. Martin Buckland, Chief Business Officer, Astex Therapeutics, Cambridge, UK The book presents a number of innovative ideas, illustrated with practical examples that should improve decision-making in the drug development process, intellectual property evaluation, licensing and sublicensing.
The authors make a persuasive case for the use of advanced techniques and the section on worked-examples should be particularly appealing to practitioners. Martin Grossmann, Novartis Pharmaceuticals There is no doubt that this book will become an essential reference tool for professionals in technology transfer, business developers and biotech companies, as well as the pharmaceutical industry and Life Science investors.
There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts.
The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies.